Additionally, cathepsin B enhances tumor progression by proteolytic degradation of the metalloprotease inhibitors, TIMP-1 and TIMP-2, and by release of growth factors VEGF and TGF-β1 bound to the ECM proteins [10–12]. Here, CTSB is linked to neoplasm.